Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD9793
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
AZD9793 is a first-in-class trispecific T-cell engager (TriTE) antibody developed by AstraZeneca for the treatment of advanced or metastatic solid tumors, with a primary focus on hepatocellular carcinoma. It is designed to target glypican-3 (GPC3) on tumor cells and recruit CD8+ T cells via CD8 engagement while also modulating the T-cell receptor (TCR). This selective recruitment aims to enhance cytotoxic potency against GPC3-positive tumor cells and minimize cytokine release syndrome by reducing CD4+ T cell activation. The drug is administered intravenously or subcutaneously and is currently being evaluated in Phase 1/2 clinical trials as monotherapy for patients with advanced solid tumors, particularly hepatocellular carcinoma[1][2][4][5].
02
Targets
CD8A (CD8 alpha/beta Coreceptor)GPC3 (Glypican-3)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on AZD9793.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD9793.